Adicet Bio (ACET) Cash from Investing Activities (2017 - 2026)

Adicet Bio's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $18.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 759.87% year-over-year to $18.9 million; the TTM figure through Mar 2026 stood at $24.1 million (up 119.8% YoY), while the FY2025 annual figure was $2.4 million, up 102.01% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $18.9 million, up from -$44.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $33.0 million in Q2 2025, with the low at -$96.6 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is -$1.9 million (2023), against an average of -$7.0 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 16164.71% in 2024, then surged 11011.59% in 2025.
• Adicet Bio's Cash from Investing Activities stood at -$6.5 million in 2022, then surged by 97.9% to -$136000.0 in 2023, then plunged by 16164.71% to -$22.1 million in 2024, then tumbled by 101.33% to -$44.5 million in 2025, then surged by 142.39% to $18.9 million in 2026.
• Business Quant data shows ACET's Cash from Investing Activities at $18.9 million in Q1 2026, -$44.5 million in Q4 2025, and $16.8 million in Q3 2025.